Abstract: The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof.

Abstract: The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof

Abstract: Disclosed are a novel azide compound represented, for example, by the formula, ##STR1## wherein R.sub.f represents a fluoroalkyl or fluoroalkylpolyether group, ##STR2## wherein R represents a divalent organic group having an ester bond, and R.sub.f ' represents a fluoroalkylpolyether group, and a novel diacylhydrazine compound having a fluoroalkylpolyether group in the side chain and lubricants containing them. When this lubricant is coated onto the carbonaceous protective film of magnetic recording media and reacted by the action of light or heat, it strongly bonds or adheres to the protective film. Thus, the durability of the lubricant improves, as a result of which a high-density magnetic recording medium having a high reliability and long life can be obtained.